EUCTR2015-004794-33-PL进行中（未招募）1 期
Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients age 18 through 80 years, inclusive.
- •2. Diagnosis of end-stage renal disease (ESRD) receiving hemodialysis for at least 3 months prior to the Screening Period
- •3. Able to receive conventional hemodialysis (i.e., not hemofiltration or hemodiafiltration) during the study
- •4. Pruritus present for at least 6 weeks
- •5. Mean pruritus severity score on a numerical rating scale (NRS) > 4 from the Screening Period (based on a minimum of 8 scores)
- •6. Patient-Assessed Disease Severity Scale Type B or C at the Screening Period
- •7. If receiving H1 antihistamines for pruritus treatment, the drug and dose has been stable during the 2 weeks prior to Screening and is expected to remain stable throughout the study
- •8. Hemoglobin > 8 g/dL at the Screening Period
- •9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2 X the upper limit of normal (ULN) at the Screening Period
- •10. Documentation of a urea reduction ratio (URR) >65% or single-pooled Kt/V >1.4 during the Screening Period
- •11. Sufficient manual dexterity to use the hand-held nebulizer or a caregiver who can reliably assist with assembly and use of the nebulizer
- •12. Adequate venous access for blood drawing, unless the dialysis access will be used for this purpose
- •13. Willingness and ability to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator
- •2. Myocardial infarction within 6 months or unstable angina, acute coronary syndrome, or interventional coronary procedure within 2 months prior to the Screening Visit
- •3. An upper or lower respiratory tract infection (including sinus infection) within 4 weeks prior to the Screening Visit
- •4. Severely symptomatic cardiopulmonary disease defined by the use of home oxygen treatment, dyspnea at rest or with minimal exertion, uncontrolled arrhythmias (e.g. atrial fibrillation with inadequate rate control), or history of life-threatening arrhythmias (e.g. cardiac arrest or syncope related to arrhythmia)
- •5. Acute exacerbation of asthma or chronic obstructive pulmonary disease resulting in hospitalization or visit to an emergency department or urgent care clinic within 6 months of the Screening Visit
- •6. Hospitalization for any medical reason other than for a pre-planned procedure or dialysis access related procedure within the 2 weeks prior to the Baseline Visit
- •7. Known malignancy for which the patient is receiving active treatment with a systemic drug
- •8. Participation in any other investigation drug study within 4 weeks prior to the Screening Visit
- •9. Use of cromolyn sodium within 2 weeks of the Screening Visit
- •10. Current (i.e., within 2 weeks prior to Screening) or anticipated use of baclofen, gabapentin, pregabalin and nalbuphine for the treatment of pruritus during the study (Note: Use of these medications for indications other than pruritus is permitted if the dose has been stable during the 2 weeks prior to Screening and is anticipated to remain stable during the study)
- •11. Current (i.e., within 2 weeks prior to Screening) or anticipated use during the study of glucocorticoids administered intravenous, oral, or transdermally (Note: Use of inhaled, intranasal, intrarticular, otic, and ophthalmic glucocorticoids is permitted during the study)
- •12. Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study (e.g., abstinence, combination barrier and spermicide, or hormonal)
- •13. History of hypersensitivity or intolerance to cromolyn sodium
- •14. Anticipated changes in the dialysis regimen or modality during the trial (e.g., change in type of filter, increase or decrease in prescribed dialysis duration by 1 hour, change or in prescribed blood flow by >100 mL/minute that is expected to significantly affect dialysis clearance as determined by the investigator) or any such changes during the 2 weeks prior to the Screening Period
研究者
相似试验
已完成
2 期
Treatment of Uremic Pruritus With PA101BUremic PruritusNCT02696499Patara Pharma70
已完成
不适用
Study on the effect of PRP on the treatment of urinary incontinenecestress urinary incontinence.Stress incontinence (female) (male)IRCT20171201037697N1Kerman University of Medical Sciences20
进行中（未招募）
1 期
Treatment with Botox in patients with urinary incontinence (accidental loss of urine) due to neurogenic detrusor overactivity (bladder problems resulting from disease or damage to the nervous systemrinary incontinence due to neurogenic detrusor overactivityMedDRA version: 18.0Level: PTClassification code 10029279Term: Neurogenic bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2014-004641-27-BEZLeuven30
尚未招募
2 期
Clinical study on the treatment of upper urinary tract calculi under the guidance of traditional Chinese medicine stone-removing exerciseITMCTR2000003587onghua Hospital Shanghai University of Traditional Chinese Medicine
进行中（未招募）
1 期
Treatment of Bladder Pain Syndrome with Onabotulinum toxin ABladder Pain SyndromeMedDRA version: 20.0Level: LLTClassification code 10071166Term: Bladder pain syndromeSystem Organ Class: 100000004857EUCTR2014-001013-81-PTCentro Hospitalar de São João, EPE30